Get intelligentvalue.com

Own it today or select a payment plan

Buy Now$3,879Payment Plan$325/mo

Secured by Stripe

Premium Domain Name

intelligentvalue.com

is available for purchase

51 views

Visitors from

US 54%·

AU 32%·

IN 7%·

GB 2%·

FR 2%

Perfect for

Financial Consulting Technology Startups Educational Services Economic Forecasting E-commerce Solutions Business Analytics Artificial Intelligence Solutions Investment Advisory Strategic Planning Market Research

Unlock the potential of 'intelligentvalue.com', a premium domain that embodies sophistication and expertise in investment advisory and financial consulting. Perfect for businesses in artificial intelligence solutions, market research, and strategic planning, this memorable domain conveys a strong branding message that resonates with clients seeking innovative and data-driven insights. Elevate your presence in the competitive landscape with a digital identity that signifies intelligence, value, and forward-thinking solutions.

Safe & Secure

Protected transactions with Stripe

Fast Transfer

Domain transferred within 24 hours

Flexible Payments

Interest-free payment plans available

Bio-Techne (TECH) Shares Skyrocket, What You Need To Know

September 30, 2025 at 16:00 PM EDT

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

TECH Cover Image

What Happened?

Shares of life sciences company Bio-Techne (NASDAQ: TECH) jumped 5.3% in the afternoon session after reports revealed a potential drug-pricing agreement between the White House and the pharmaceutical industry.

The Trump administration is advancing its “Most Favored Nation” initiative, which aims to lower prescription drug costs for Americans. This policy would tie the prices of medications in the U.S. to the lowest costs paid by other wealthy nations.

As part of this push, Pfizer has reportedly entered into an agreement to voluntarily sell its medications through Medicaid at these reduced prices. The move comes as the administration intensifies pressure on drugmakers to make prices more affordable. While pricing controls can often be a headwind, the market's positive reaction suggests that investors may see this voluntary agreement as a way to resolve regulatory uncertainty, providing a clearer path forward for the industry.

The shares closed the day at $55.64, up 6.5% from previous close.

Is now the time to buy Bio-Techne? Access our full analysis report here, it’s free.

What Is The Market Telling Us

Bio-Techne’s shares are quite volatile and have had 19 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business.

The previous big move we wrote about was 20 days ago when the stock dropped 4.8% on the news that the company presented a cautious outlook at the Baird Global Healthcare Conference, highlighting significant market challenges despite some areas of growth.

During the presentation, Bio-Techne reported 3% organic growth for the fourth quarter, driven by double-digit growth in its pharma segment and in China. However, this positive news was overshadowed by hurdles in other key areas. The company noted a decline in the U.S. academic market and pointed to unpredictability in the biotech sector, which is suffering from "dramatic funding declines."

Management stated it is navigating these uncertain market conditions with a cautious approach, which appears to have concerned investors about the company's near-term performance.

Bio-Techne is down 22.2% since the beginning of the year, and at $55.63 per share, it is trading 30.4% below its 52-week high of $79.93 from September 2024. Investors who bought $1,000 worth of Bio-Techne’s shares 5 years ago would now be looking at an investment worth $898.24.

Today’s young investors won’t have read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next.

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article

Symbol

Price

Change (%)

AMZN

238.55

-2.96 (-1.23%)

AAPL

291.13

-4.50 (-1.52%)

AMD

511.57

+23.12 (4.73%)

BAC

56.02

+0.86 (1.56%)

GOOG

358.16

+1.60 (0.45%)